Latest Conference Articles

“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.

Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.

Increased risk of AF by fish oil supplement was found to be prominent in low­ risk participants with healthy lifestyles.

Full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications in critically-ill patients with COVID-19.

Digital screening more than doubled the detection rate of treatment-relevant AF in both phases of eBRAVE-AF trial.

Targeting a mean arterial blood pressure of 77 mm Hg or 63 mm Hg was not associated with significantly different percentages of patients dying or having severe disability or coma.

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure.

Treatment adherence remains a concern in psychiatry.

The treatment strategy led to lower risk of major adverse cardiovascular events than usual care in older patients with recent myocardial infarction.

The FDA approved esketamine in 2019 for major depressive disorder.

Postpartum depression rates have increased since the COVID-19 pandemic.

Alcohol, stress, drug use, and not seeking help are all risk factors for chronic depression.

CBD has shown promise in treating anxiety and psychosis.

There remains a need for better treatments for bipolar disorder when it is identified early.

Mixed feature depression can be difficult to diagnose because the symptoms can be similar to other psychiatric disorders.

There remains a need for more research into the connection between grief and depression following a death.

Borderline personality disorder remains one of the most difficult to understand conditions in psychiatry.

Esketamine is seen as a major breakthrough in finding more treatments for depression.

Dr. Shear talked about the similarities and differences between depression and grief and the importance of recognizing both.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

Over 60% of patients in the second year of TENAYA and LUCERNE were on 16 week dosing in the faricimab group.

Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.

Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.

The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.

A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.

Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).

Data show metformin was associated with reduced odds of developing AMD, with low to moderate doses having the greatest potential benefit.

Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.